Pleiotropic and Renoprotective Effects of Erythropoietin Beta on Experimental Diabetic Nephropathy Model

Nephron

Volumn 132, Issue 4, 2016, Pages 292-300

  Eren, Zehra ^b   Günal, Mehmet Yalçln ^a   Arl, Elif ^b   Çoban, Jale ^b   Cąkalaǧaoǧlu, Fulya ^c   Cąǧlayan, Burak ^a   Beker, Mustafa Cąǧlar ^a   Akdeniz, Tuba ^b   Yanlkkaya, Gülderen ^b   Klllç, Ertuǧrul ^b   Kantarcl, Gülçin ^b  

^a ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

^b YEDITEPE UNIVERSITY   (Turkey)

^c IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

Author keywords

Diabetic nephropathy; Erythropoietin beta; Rat model

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CREATININE; GAMMA INTERFERON; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INTERLEUKIN 1BETA; INTERLEUKIN 4; MALONALDEHYDE; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT ERYTHROPOIETIN; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE; ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; EXPERIMENTAL DIABETIC NEPHROPATHY; HISTOLOGY; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY PARENCHYMA; KIDNEY TUBULE DAMAGE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RENAL PROTECTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; BLOOD; DIABETIC NEPHROPATHIES; DISEASE MODEL; ENZYMOLOGY; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; CYTOKINES; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; GLUTATHIONE; INFLAMMATION MEDIATORS; MALE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE;

EID: 84961233580     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000444649     Document Type: Article

References (26)

1. Reutens AT, Atkins RC: Epidemiology of diabetic nephropathy. Contrib Nephrol 2011; 170: 1-7.
2. Ritz E, Rychlik I, Locatelli F, Halimi S: Endstage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808.
3. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, et al: Erythropoiesisstimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014; 12: CD010590.
4. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2: 279-335.
5. Toba H, Nakashima K, Oshima Y, Kojima Y, Tojo C, Nakano A, Wang J, Kobara M, Nakata T: Erythropoietin prevents vascular inflammation and oxidative stress in subtotal nephrectomized rat aorta beyond haematopoiesis. Clin Exp Pharmacol Physiol 2010; 37: 1139-1146.
6. Schiffer M, Park JK, Tossidou I, Bartels J, Shushakova N, Menne J, Fliser D: Erythropoietin prevents diabetes-induced podocyte damage. Kidney Blood Press Res 2008; 31: 411-415.
7. Chen LN, Sun Q, Liu SQ, Hu H, Lv J, Ji WJ, et al: Erythropoietin improves glucose metabolism and pancreatic cell damage in experimental diabetic rats. Mol Med Rep 2015; 12: 5391-5398.
8. Kitada M, Takeda A, Nagai T, Ito H, Kanasaki K, Koya D: Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty (fa/fa) rats: a model of type 2 diabetes. Exp Diabetes Res 2011; 2011: 908185.
9. Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358.
10. Beutler E, Duron O, Kelly BM: Improved method for the determination of blood glutathione. J Lab Clin Med 1963; 61: 882-888.
11. Mylroie AA, Collins H, Umbles C, Kyle J: Erythrocyte superoxide dismutase activity and other parameters of copper status in rats ingesting lead acetate. Toxicol Appl Pharmacol 1986; 82: 512-520.
12. Lawrence RA, Burk RF: Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun 1976; 71: 952-958.
13. Habig WH, Jakoby WB: Assays for differentiation of glutathione S-transferases. Methods Enzymol 1981; 77: 398-405.
14. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC: Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76-85.
15. Maluf SW, Marroni NP, Heuser VD, Pra D: DNA damage and oxidative stress in human disease. Biomed Res Int 2013; 2013: 696104.
16. Rabbani N, Thornalley PJ: Dicarbonyl proteome and genome damage in metabolic and vascular disease. Biochem Soc Trans 2014; 42: 425-432.
17. Bartnicki P, Fijakowski P, Majczyk M, Baszczyk J, Banach M, Rysz J: Effect of methoxy polyethylene glycol-epoetin beta on oxidative stress in predialysis patients with chronic kidney disease. Med Sci Monit 2013; 19: 954-959.
18. Dang J, Jia R, Tu Y, Xiao S, Ding G: Erythropoietin prevents reactive oxygen species generation and renal tubular cell apoptosis at high glucose level. Biomed Pharmacother 2010; 64: 681-685.
19. Toba H, Sawai N, Morishita M, et al: Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. Eur J Pharmacol 2009; 612: 106-114.
20. Sanchis-Gomar F, Garcia-Gimenez JL, Pareja-Galeano H, Romagnoli M, Perez-Quilis C, Lippi G: Erythropoietin and the heart: physiological effects and the therapeutic perspective. Int J Cardiol 2014; 171: 116-125.
21. Wiedenmann T, Ehrhardt S, Cerny D, et al: Erythropoietin acts as an anti-inflammatory signal on murine mast cells. Mol Immunol 2015; 65: 68-76.
22. Noh MY, Cho KA, Kim H, Kim SM, Kim SH: Erythropoietin modulates the immune-inflammatory response of a SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS). Neurosci Lett 2014; 574: 53-58.
23. Zhang J, Zou YR, Zhong X, et al: Erythropoietin pretreatment ameliorates renal ischaemia-reperfusion injury by activating PI3K/Akt signalling. Nephrology (Carlton) 2015; 20: 266-272.
24. Lu J, Yao YY, Dai QM, et al: Erythropoietin attenuates cardiac dysfunction by increasing myocardial angiogenesis and inhibiting interstitial fibrosis in diabetic rats. Cardiovasc Diabetol 2012; 11: 105.
25. Geng XC, Hu ZP, Lian GY: Erythropoietin ameliorates renal interstitial fibrosis via the inhibition of fibrocyte accumulation. Mol Med Rep 2015; 11: 3860-3865.
26. Zivkovi M, Djuri T, Stojkovi L, Jovanovi I, Konar I, Davidovi L, et al: CXCL16 haplotypes in patients with human carotid atherosclerosis: preliminary results. J Atheroscler Thromb 2015; 22: 10-20.